Introduction {#s1}
============

The evolutionary transition from simple chordate body plans to complex vertebrate body plans was driven by the acquisition of the Neural Crest, a unique stem cell population with broad, multi-germ layer developmental potential ([@bib32]; [@bib14]; [@bib3]; [@bib44]). At gastrula and neurula stages, Neural Crest cells are found within the presumptive ectoderm at the neural plate border, and they will ultimately contribute to ectodermal derivatives, including much of the peripheral nervous system. However, despite their site of origin, neural crest cells also contribute many mesodermal cell types to the body plan, including cartilage, bone, and smooth muscle, and also make contributions to otherwise endodermal organs such as the thyroid ([@bib32]). Until recently, models for how neural crest cells acquire their remarkably broad potential proposed that inductive interactions orchestrated by BMP, FGF, and Wnt signals endowed these cells with greater potency than the cells they were derived from developmentally or evolutionarily ([@bib22]; [@bib52]; [@bib44]; [@bib46]; [@bib50]). Such a mechanism conflicts, however, with the generalized view of embryonic development as a progressive restriction of developmental potential.

We recently demonstrated that much of the regulatory network which controls the pluripotency of blastula inner cell mass/animal cap cells is shared with neural crest cells, shedding new light on the origins of the neural crest cells and the evolution of vertebrates ([@bib5]). Indeed, we found that factors that have long been considered neural crest potency factors, such as Snail1 ([@bib52]) and Sox5 ([@bib41]), are expressed earlier, in blastula animal pole cells, and are required for their pluripotency. Together, these findings suggest that neural crest cells arise through retention of the transcriptional circuitry that controls the pluripotency of the blastula cells they are derived from, avoiding the lineage restriction that characterizes neighboring cells ([@bib5]; [@bib21]; [@bib33]). This revised model raises fundamental questions about how the cells that will become the neural crest escape lineage restriction in order to maintain broad developmental potential, and how this relates to signals that have previously been implicated in the genesis of these stem cells. For example, BMP signaling has been found to play an essential role in the pluripotency of both blastula stem cells and neural crest cells ([@bib59]; [@bib25]; [@bib41]), together with Sox5, which directs the target specificity of BMP R-Smads in both cell types ([@bib41]). It will be important to build on these insights and further delineate the roles of other signaling pathways in the retention of pluripotency.

FGF signaling is used reiteratively throughout embryonic development to pattern multiple tissue types and germ layers. While FGF signaling has a well established role in the formation of mesoderm, it has also been linked to the formation of the neuroectoderm/neural plate, as well as to anterio-posterior patterning of the CNS ([@bib49]; [@bib2]; [@bib57]; [@bib20]; [@bib16]; [@bib45]; [@bib8]; [@bib7]; [@bib56]). While anterior neural induction mediated by BMP antagonists can occur independent of FGF signaling, FGFs clearly play a role in posterior neural development ([@bib56]). Importantly, FGF signaling has also been implicated in the establishment of both neural crest stem cells and the neural plate border region more generally ([@bib36]; [@bib27]; [@bib37]; [@bib18]; [@bib51]; [@bib58]). Although the precise role of FGF signaling in the establishment of these cell populations relative to BMP or Wnt signals is not fully understood, at least some enhancers for neural plate border genes have been shown to require FGF signaling ([@bib10]). Intriguingly, these same genes are also expressed in pluripotent blastula cells, making it important to re-examine the role of FGF-mediated signals at earlier times in *Xenopus* development, with a focus on understanding their role in the retention of blastula stage pluripotency proposed to underlie genesis of Neural Crest cells. Such studies might also help shed light on the highly context dependent role played by FGF signaling in the regulation of pluripotency in cultured embryonic stem (ES) cells ([@bib30]). Activation of FGF signaling in naïve mouse embryonic stem cells (mESCs) promotes lineage restriction of these cells ([@bib26]), whereas FGF activity maintains primed embryonic stem cells, also known as epiblast stem cells (EpiSCs) in a pluripotent/undifferentiated state ([@bib4]; [@bib53]). Given our model that neural crest cells arise via retention of the attributes of pluripotent blastula cells, we wondered if FGF signaling might play a role in preventing premature lineage restriction of these cells.

In this study, we investigate the requirement for FGF signaling in the transient pluripotency of blastula animal pole cells, and the subsequent establishment of the neural crest state. We find that FGF signaling is essential for normal gene expression in pluripotent blastula cells, and for the capacity of these cells to respond properly to lineage restriction cues. We investigate which FGF-dependent signaling cascades mediate these effects, and find a striking switch in cascade utilization as cells transit from a pluripotent state to a lineage restricted state. We show that pluripotent blastula cells exhibit high Map Kinase signaling, whereas cells undergoing lineage restriction are characterized by increased PI3 Kinase/Akt signaling. Finally, we provide evidence that the balance of FGF-directed Map Kinase and PI3 Kinase/Akt signaling activity plays a role in the retention of blastula stage potential in neural crest cells.

Results {#s2}
=======

FGF signaling is required for proper gene expression in pluripotent blastula cells {#s2-1}
----------------------------------------------------------------------------------

Because FGF signaling is known to play a role in the establishment of the neural crest cell population at the neural plate border in *Xenopus,* and is also linked to the control of pluripotency in mESCs, we sought to determine if these signals were required in the pluripotent animal pole cells of blastula stage embryos. Consistent with such a role, FGF receptor 4 (FGFR4) is expressed throughout the animal hemisphere of blastula stage embryos, where the pluripotent stem cells reside. By gastrula stages (St. 12), *FGFR4* expression is heightened in the neural plate border region, and by neurula stages (St. 15) is strongly enriched in neural crest forming regions of the embryo ([Figure 1a](#fig1){ref-type="fig"}). The expression pattern of FGFR4 at gastrula and neurula stages has been previously described ([@bib20]; [@bib11]; [@bib34]), and its expression in neural crest forming regions at neurula stages has been reported to overlap with that of Snail2 ([@bib11]) in agreement with our unpublished observations.

![FGF signaling is required for proper blastula stage gene expression.\
(**A**) In situ hybridization examining *FGFR4* expression in wildtype *Xenopus* embryos collected at blastula (stage 9, lateral view, animal pole up), late gastrula (stage 12, dorsal view, anterior up), and mid-neurula (stage 15, dorsal view, anterior up) stages. Expression is seen in the pluripotent cells of the animal hemisphere at blastula stages and in the neural plate and neural crest forming regions at gastrula and neurula states. (**B**) Animal pole explant assay examining *FGFR4* expression. Explants were cultured alongside sibling embryos and collected at blastula (stage 9), late gastrula (stage 12), and mid-neurula (stage 15) stages. (**C**) In situ hybridization examining *Vent2, Id3, Myc,* and *FoxD3* expression in blastula stage (stage 9) embryos injected with dominant-negative FGFR4 (dnFGFR4). Asterisk denotes injected side, marked by staining of the lineage tracer β-galactosidase (red). Dominant-negative FGFR4 blocks expression of *Vent2* and *Id3.*](elife-33845-fig1){#fig1}

To determine whether *FGFR4* expression correlates with the stem cell state, we utilized explants of pluripotent blastula stem cells ('animal caps'). At blastula stages, these explants are pluripotent and can be induced to give rise to any embryonic cell type. The pluripotency of these cells is transient in culture, however, as it is in the developing embryo. As explants age from blastula to gastrula then neurula stages, they lose pluripotency and become lineage restricted; in the absence of exogenous signals, they will transit to an epidermal state. We therefore examined expression of *FGFR4* in these explants as they aged. We found that at blastula stages, when explanted cells are pluripotent, they strongly express *FGFR4* ([Figure 1b](#fig1){ref-type="fig"}), however, as these cells transit to an epidermal state, *FGFR4* expression is lost. This expression pattern is consistent with a role for this receptor in events prior to the onset of lineage restriction. However, although *FGFR4* is the most abundant FGFR in these cells (unpublished data), other FGFRs are also expressed ([@bib34]) and thus could play roles in control of pluripotency and lineage restriction.

In order to determine whether FGF signaling plays a role in pluripotency and lineage restriction in *Xenopus*, we used a dominant-negative inhibitory receptor to carry out loss of function studies. We chose a dominant negative strategy because we were interested in the overall role of FGF-mediated signals, rather than role of any specific receptor. While we mainly deployed a dominant negative FGFR4 for these studies, dominant negative receptors frequently inhibit the activity of other related receptors and its effects should therefore be interpreted as effects on FGF signaling in general, not on FGFR4 signaling specifically. Embryos expressing a dominant-negative FGFR4 (dnFGFR4) were cultured to blastula stages and examined by in situ hybridization for genes expressed by pluripotent animal pole cells. We found that blocking FGF signaling led to a significant reduction in the expression of both *Vent2* (98%, n = 186) and *Id3* (96%, n = 84), but did not alter expression of other factors such as *Myc* or *FoxD3* ([Figure 1c](#fig1){ref-type="fig"}). The requirement for FGF signaling for proper gene expression in pluripotent animal pole cells suggests an essential role for these signals in controlling the developmental state of these cells. We similarly found that cells expressing dnFGFR4 were deficient in their ability to give rise to neural crest cells in whole embryos, as assayed by expression of *FoxD3*, *Sox9* and *Snail2* ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). By contrast, we found that expression of a dnFGFR1 did not similarly lead to loss of neural crest formation, suggesting that these two dominant negative receptors have distinct activities. We thus utilized dnFGFR4 to block FGF signaling for subsequent experiments, while recognizing that it may block FGF receptors other than FGFR4.

Blocking FGF signaling in pluripotent blastula cells interferes with the adoption of an epidermal state {#s2-2}
-------------------------------------------------------------------------------------------------------

Since blocking FGF signaling inhibited expression of *Vent2* and *Id3* in pluripotent blastula cells, we hypothesized that FGF signaling might be required for the pluripotency of these cells, and/or for cells to exit pluripotency and transit to a restricted state. At blastula stages, when cells are pluripotent, animal pole explants express core pluripotency markers such as *Sox2/3*, and the Oct4 homologue, *Oct60* (*pou5F3.3*). These genes are subsequently down-regulated as explants age and become restricted to an epidermal state. To test the requirement for FGF signaling in this process, embryos injected with dnFGFR4 were allowed to develop until blastula stages, when animal cap explants were isolated, and then cultured until sibling embryos reached blastula (St.9), gastrula (St.11) or neural plate (St.13) stages. We found that explants blocked for FGF signaling exhibited prolonged, low level expression of *Sox3 (*95%, n = 97), and poorly expressed the epidermal marker *Epidermal Keratin (EPK)* (90%, n = 62), suggesting that FGF signaling was essential for pluripotent blastula cells to transit to an epidermal state ([Figure 2a,c](#fig2){ref-type="fig"}). Since *Sox3* expression is characteristic of both pluripotent cells and neuronal progenitor cells, we investigated whether explants expressing dnFGFR4 were being retained in a pluripotent state or instead were being biased toward a neuronal progenitor fate. We found that Stage 13 explants blocked for FGF signaling do not express the pluripotency factor *Oct60* (*pou5F3.3*), suggesting that they are not retaining pluripotency ([Figure 2b](#fig2){ref-type="fig"}). These explants do weakly express the definitive neural marker *Nrp1* (94%, n = 85), suggesting that they may be biased toward a neuronal progenitor state. However, the explants do not express levels of either *Sox3* or *Nrp1* associated with chordin-mediated neural induction, indicating that they are not adopting a definitive neural state ([Figure 2c,d](#fig2){ref-type="fig"}). It is possible that, as previously reported, FGF signals are later involved in the commitment of these cells to a neuronal state in response to neural-inducing cues ([@bib20]). Our experiments do not address this question.

![Blocking FGF signaling in pluripotent blastula cells interferes with adoption of an epidermal state and neuralizes cells.\
(**A--D**) In situ hybridization examining expression of *Epidermal Keratin (EPK)* (**A**) *Oct60* (**B**) *Sox3* (**C**) or *Nrp1* (**D**) in animal pole explants injected with dnFGFR4 or chordin for phenotypic comparison. Explants were cultured alongside sibling embryos and collected at blastula (stage 9), midgastrula (stage 11), and early neurula (stage 13) stages. Blocking FGF signaling interferes with *EPK* expression and mildly induces *Nrp1* expression.](elife-33845-fig2){#fig2}

Cells progress from a high pERK state to a high pAkt state as they transit from the pluripotent to the lineage-restricted state {#s2-3}
-------------------------------------------------------------------------------------------------------------------------------

Like other tyrosine kinase receptors, FGF receptors can activate multiple downstream signaling cascades upon ligand binding, including the Ras/Map Kinase cascade that leads to Erk phosphorylation and activation, and the PI3 Kinase cascade that leads to Akt phosphorylation and activation ([Figure 3a](#fig3){ref-type="fig"}). Both of these signaling cascades have previously been implicated in Neural Crest development ([@bib51]; [@bib42]). Given our findings that FGF signaling plays an essential role in pluripotent blastula cells, we wished to determine which signaling cascades were activated by FGF signaling in these cells during the transition from pluripotency to lineage restriction.

![FGF signaling directs the transit from a pluripotent to a lineage restricted state through regulation of Erk and Akt activation.\
(**A**) Schematic representation of the FGF receptor and select signaling cascades activated downstream, highlighting the Ras/MAPK (Erk) and PI3K/Akt cascades. (**B**) Western blot of lysates from animal pole explants cultured alongside sibling embryos and collected at blastula (stage 9), midgastrula (stage 11), and early neurula (stage 13) stages to examine levels of phosphorylated and unphosphorylated Erk1/2 and Akt. Pluripotent cells show high pErk while lineage restricted cells display high pAkt. (**C**) Western blot of lysates from animal pole explants injected with dnFGFR4. Explants were cultured alongside sibling embryos and collected at blastula (stage 9) and early neurula (stage 13) stages to examine levels of phosphorylated and unphosphorylated Erk1/2 and Akt. Both pErk and pAkt are blocked by dnFGFR4. (**D**) Animal pole explant assay examining *Epidermal Keratin (EPK)* and *Trim29* expression in explants injected with either dnFGFR4 or dominant- negative PI3K (dnPI3K) or treated with Meki (RDEA119) and collected alongside sibling embryos at early neurula stages (stage 13--14). Meki treatment phenocopies dnFGFR4.](elife-33845-fig3){#fig3}

To assess the activation of these two cascades, we utilized antibodies that detect the phosphorylated, active, forms of Map Kinase and Akt. Animal pole explants were isolated at blastula stages and collected at blastula, gastrula, or early neural plate stages for western analysis. Unexpectedly, we detected a striking transition in cascade activation as cells transited from a pluripotent to a lineage-restricted state. Pluripotent cells of blastula-stage explants exhibited robust phosphorylated-Erk (pErk), which was lost as cells became lineage-restricted ([Figure 3b](#fig3){ref-type="fig"}). By contrast, pluripotent cells showed low or undetectable phosphorylated-Akt (pAkt), but activation of this kinase increased as cells lost pluripotency and transited to an epidermal state. Both the early pErk signal and the later pAkt signal were blocked in explants expressing dnFGFR4, confirming that both were FGF signaling-dependent ([Figure 3c](#fig3){ref-type="fig"}).

Because the above findings implicate two different signaling cascades in FGF-mediated regulation of pluripotency and lineage restriction, and because these signaling cascades appear to play temporally distinct roles in this transition, we wished to determine the contributions that each pathway makes to the developmental potential of these cells. To address this, we utilized reagents that can block the activation of each pathway. Map Kinase signaling was blocked using a chemical inhibitor of the upstream kinase Mek, RDEA119 ([@bib24]), ('Meki') or using a dominant negative form of Raf1 ('dnRaf'). Activation of Akt signaling was blocked by over-expressing a dominant-negative PI3 Kinase subunit (Δp85, 'dnPI3K') ([@bib6]; [@bib40]) or using a chemical inhibitor of PI3 kinase, LY294 or Wortmannin ('PI3Ki'). We confirmed that these inhibitors blocked the activation of its respective cascade without interfering with the other pathway ([Figure 3---figure supplement 1a,b](#fig3s1){ref-type="fig"}). We then compared the effects of each of these inhibitors to dnFGFR4 in animal pole explants. We found that blocking Map Kinase signaling phenocopied the effects of blocking FGF signaling, preventing cells from transiting to an epidermal state, as evidenced by a loss of two different epidermal markers *EPK* (85%, n = 56) and *Trim29* (100%, n = 25) ([Figure 3d](#fig3){ref-type="fig"}). By contrast, blocking PI3 Kinase/Akt signaling with dnPI3K or with the chemical inhibitor LY294 had no effect on *EPK* or *Trim29* expression ([Figure 3d](#fig3){ref-type="fig"} and not shown). These findings reveal a differential requirement for Map Kinase and PI3 Kinase/Akt signaling during the transition from a pluripotent to an epidermal state.

PI3K/AKT signaling, but not MAPK signaling, is required for pluripotent blastula cells to adopt a neural fate {#s2-4}
-------------------------------------------------------------------------------------------------------------

Given the strikingly different responses of pluripotent animal pole cells to blocking Map Kinase vs. PI3 Kinase/Akt signaling with respect to adopting an epidermal state, we wished to examine the role these pathways play in adopting an alternative ectoderm-derived state, neuronal progenitor cells. It is well established that blocking BMP signaling with BMP antagonists such as Chordin directs cells to form neural plate rather than epidermis ([@bib48]; [@bib60]). We therefore examined the effects of blocking Map Kinase or PI3 Kinase/Akt on Chordin-mediated neural induction. Chordin expressing animal pole explants, but not control explants, strongly express the neuronal progenitor markers *Sox2* and *Sox3* at Stage 13, and the definitive neural marker *Nrp1* at stage 18. Inhibition of the PI3 Kinase/Akt cascade prevented cells from adopting a neuronal state in response to Chordin, as evidenced by decreased expression of *Sox2* (92%, n = 26), *Sox3* (100%, n = 28), and *Nrp1* (96%, n = 28) ([Figure 4b](#fig4){ref-type="fig"}). Similar results were obtained by blocking the PI3 Kinase/Akt cascade with the PI3 Kinase inhibitors LY294 and Wortmannin ([Figure 4---figure supplement 1b,c](#fig4s1){ref-type="fig"}). By contrast, blocking the Map Kinase cascade with RDEA119 did not interfere with expression of *Sox3* (93%, n = 27) or *Nrp1* (100%, n = 25), suggesting that this pathway is not essential for neural fates ([Figure 4a](#fig4){ref-type="fig"}). Similarly, blocking the Map Kinase cascade using a dominant-negative Raf1 (dnRaf) did not block Chordin-mediated neural induction ([Figure 4---figure supplement 1a](#fig4s1){ref-type="fig"}). Interestingly, we found that RDEA119 could interfere with Chordin-mediated *Sox2* expression in response to low levels of Chordin (92%, n = 26) but not high ([Figure 4a](#fig4){ref-type="fig"} and not shown).

![PI3K/Akt signaling but not MAPK signaling is required for pluripotent blastula cells to transit to a neural progenitor state.\
(**A--B**) Animal pole explant assay examining *Sox2*, *Sox3,* and *Nrp1* expression in Chordin (Chd) induced animal cap explants treated with Meki (RDEA119) (**A**) or injected with dnPI3K (**B**). Explants were cultured alongside sibling embryos and collected at early neurula stages (stage 13) for *Sox2/3* or late neurula stages (stage 18) for *Nrp1*. Meki treatment does not affect Chordin-mediated neural induction whereas dnPI3K blocks induction of all three neural markers.](elife-33845-fig4){#fig4}

MAPK signaling and PI3K/Akt signaling are differentially required for transit to non-ectodermal lineages {#s2-5}
--------------------------------------------------------------------------------------------------------

Pluripotent animal pole cells can adopt mesodermal and endodermal fates, in addition to ectoderm-derived fates, under appropriate inducing conditions. Given our findings that Map Kinase and PI3 Kinase/Akt signaling are differentially required for these cells to transit to epidermal versus neuronal progenitor states, we further investigated the roles of these pathways in the formation of mesoderm and endoderm. The TGF-beta signaling pathway plays a central role in the formation of these two germ layers, and the ability of the ligand activin to induce mesodermal and endodermal states in a dose-dependent manner has been well documented ([@bib12]; [@bib54]; [@bib23]). Treatment of control animal pole explants with low levels of activin is sufficient to promote a mesodermal state, as evidenced by high levels of *Xbra* and *MyoD*. We found that blocking activation of Map Kinase in these explants led to a complete loss of this mesodermal gene expression (100%, n = 60), as did blocking PI3 Kinase/Akt signaling (98%, n = 56), demonstrating that both of these signaling pathways play essential roles in the adoption of a mesodermal fate ([Figure 5a](#fig5){ref-type="fig"}), which is consistent with previous findings ([@bib55]; [@bib6]).

![MAPK and PI3K/Akt differentially alter the transit of pluripotent cells to restricted cell states.\
(**A--B**) Animal pole explant assay examining expression of *Xbra* and *MyoD* (**A**) or *Endodermin* and *Sox17* (**B**) in explants cultured with or without activin after treatment with Meki (RDEA119) or injection with dnPI3K. Explants were cultured alongside sibling embryos and collected at midgastrula stages (stage 11.5) for *Xbra, Endodermin,* and *Sox17* expression and midneurula stages (stage 15/16) for *MyoD* expression. Blocking either cascade interferes with mesoderm formation whereas only MAPK signaling is required for *Endodermin* induction.](elife-33845-fig5){#fig5}

Treating pluripotent animal pole cells with higher doses of activin can induce endoderm formation, accompanied by expression of the primitive endodermal markers *Endodermin* and *Sox17.* We found that blocking PI3 Kinase/Akt activation had no effect on activin-mediated induction of *Endodermin* or *Sox17* in this assay, indicating that this signaling cascade is not essential for transit to an endodermal state ([Figure 5b](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1a](#fig5s1){ref-type="fig"}). By contrast, inhibition of Map Kinase activation in these explants led to a loss of *Endodermin* expression (88%, n = 58), suggesting an inability to adopt a proper endodermal fate. Interestingly, expression of *Sox17* was increased following RDEA119 treatment (100%, n = 25), showing differential regulation of these two key markers of primitive endoderm ([Figure 5b](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1a](#fig5s1){ref-type="fig"}).

Prolonged MAPK activation alters the timing of pluripotency gene expression {#s2-6}
---------------------------------------------------------------------------

A synthesis of the above findings indicates that blastula animal pole cells cannot adopt epidermal, mesodermal, or endodermal states when Map Kinase signaling is blocked, and are partially impaired in transiting to a neuronal progenitor state. We interpret these findings to mean that Map Kinase signaling is essential to the pluripotency of these cells. Consistent with this interpretation, qRT-PCR analysis of blastula stage explants treated with RDEA119 showed a significant reduction in expression of the pluripotency and blastula stage markers *Snail1*, *FoxD3*, *Zic1*, and *Sox2*, compared to control explants ([Figure 5---figure supplement 2a](#fig5s2){ref-type="fig"}). By contrast, while inhibition of PI3 Kinase/Akt signaling prevents transit to a neural or mesodermal state, it has no effect on the ability of pluripotent blastula cells to form endoderm or epidermis. Thus, this signaling pathway appears to be essential for transit to a subset of restricted states . To further understand the role of PI3 Kinase/Akt signaling in these cells, we examined the changes in gene expression elicited by treatment of explants aged to stage 13 in the presence of the PI3 Kinase inhibitor LY294. We found that when PI3 Kinase/Akt activation was blocked, a diverse set of lineage markers were up-regulated, including *Zic2, Sox3*, Sox*17*, and *MyoD*, potentially impeding adoption of certain lineage fates ([Figure 5---figure supplement 2b](#fig5s2){ref-type="fig"}). Importantly, the differential requirements for these two signaling cascades correlates with their temporal activation in animal pole cells, with high levels of pErk and low/absent pAkt characterizing pluripotent cells, whereas a transition to high pAkt and low pErk accompanies lineage restriction.

These findings suggest that prolonged Map Kinase signaling might interfere with the transition from a pluripotent to a lineage-restricted state. To examine this we used a constitutively active version of the upstream Mek kinase (Act-Mek) to activate Map Kinase ([@bib9]) and examined the effects on expression of the pluripotency marker *Sox3* as cells transited from a pluripotent (St.9) to a lineage restricted (St.13) epidermal state. Prolonged activation of Map Kinase signaling was sufficient to maintain *Sox3* expression past the time when it would normally be down-regulated as cells lose pluripotency (92%, n = 49), leading to a 2--4 fold increase in *Sox3* expression over developmental time ([Figure 6a,b](#fig6){ref-type="fig"}). This suggests that prolonged Map Kinase signaling may delay the ability of these cells to exit the pluripotent state.

![Prolonged MAPK activation alters the timing of pluripotency gene expression.\
(**A--B**) Animal pole explant assays examining *Sox3* expression in animal cap explants injected with constitutively active Mek (Act-Mek). Explants were cultured alongside sibling embryos and collected at blastula (stage 9), midgastrula (stage 11), and early neurula (stage 13) stages for in situ hybridization (**A**) or qRT-PCR (**B**). Activating MAPK leads to retained *Sox3* expression. (**C**) Animal cap explant assay examining *Xbra* and *Endodermin* expression in explants cultured with or without activin after injection with constitutively active PI3K (Act-PI3K) or Act-Mek. Explants were cultured alongside sibling embryos and collected at midgastrula stages (stage 11.5). Sustained MAPK activity interferes with *Endodermin* induction. (ns, not significant; \*\*p\<0.01).](elife-33845-fig6){#fig6}

We also examined the effects of prolonged Map Kinase activity on the ability of blastula animal pole cells to adopt mesodermal or endodermal fates. We found that activation of the Map Kinase cascade alone also caused low-level expression of mesodermal markers (89%, n = 28), consistent with previous reports ([@bib28]), and did not interfere with activin-mediated mesoderm formation. Interestingly, activating Map Kinase did interfere with transit to an endodermal state in response to high activin (81%, n = 27) ([Figure 6c](#fig6){ref-type="fig"}). By contrast, premature activation of PI3 Kinase/Akt activity (achieved by expressing a constitutively active p110 subunit of PI3 Kinase (p110caax) \[[@bib6]; [@bib40]\]) did not affect the ability of blastula stem cells to transit to either a mesodermal or endodermal lineage in response to activin treatment, and indeed caused low-level activation of the mesodermal marker *Xbra* in the absence of activin (50%, n = 30) ([Figure 6c](#fig6){ref-type="fig"}).

Reprograming blastula stem cells to a neural crest state leads to prolonged MAPK activation at the expense of PI3K activity {#s2-7}
---------------------------------------------------------------------------------------------------------------------------

We recently proposed that Neural Crest cells arise via retention of the circuitry of pluripotency possessed by their blastula ancestors ([@bib5]; [@bib21]). Intriguingly, our current work indicates that the pluripotent state is characterized by high Map Kinase activity, and low Akt signaling. This raises the important question of whether FGF-mediated activation of Map Kinase activity may contribute to establishment of the Neural Crest state in pluripotent blastula cells, protecting them from lineage restriction, and similarly if activation of PI3 Kinase/Akt might oppose formation of the Neural Crest. To test this, we first asked if Map Kinase activity was required for establishment of the neural crest stem cell population at the neural plate border. When Map Kinase activation was blocked by expressing dnRaf, expression of neural crest markers *FoxD3, Sox9* and *Snail2* was lost. By contrast, blocking PI3 Kinase activation using the inhibitor Wortmannin did not significantly alter neural crest factor expression, despite completely blocking Akt activation ([Figure 7---figure supplement 2a,d](#fig7s2){ref-type="fig"}).

To further examine the link between establishment of the Neural Crest state and the balance between the Map Kinase and PI3 Kinase/Akt cascades, we asked if reprogramming cells to a Neural Crest state would alter the activity of these two signaling cascades. Animal pole explants can be reprogramed to a Neural Crest state by forced expression of the neural plate border factors Pax3 and Zic1 ([@bib38]; [@bib19]). Strikingly, high levels of pErk activity were maintained in these explants through stages when control explants are undergoing lineage restriction and adopting an epidermal state ([Figure 7a](#fig7){ref-type="fig"}). Similarly, reprogramed explants did not exhibit the increase in pAkt characteristic of the lineage-restricted state. These findings demonstrate that pluripotent blastula cells and Neural Crest cells share a common signature with respect to the activity of these two signaling cascades. Establishing a Neural Crest state was also accompanied by sustained expression of *FGFR4* (96%, n = 27) ([Figure 7---figure supplement 1a](#fig7s1){ref-type="fig"}).

![Reprograming cells to a Neural Crest state establishes and requires high MAPK and low PI3K/Akt activity.\
(**A**) Western blot of lysates from Pax3-GR/Zic1-GR injected animal pole explants. Explants were cultured alongside sibling embryos and collected at blastula (stage 9) and early neurula (stage 13) stages to examine levels of phosphorylated and unphosphorylated Erk1/2 and Akt. Reprograming to a neural crest state retains the activities of these pathways characteristic of pluripotent blastula cells. (**B--C**) Animal cap explant assay examining *Sox9* and *FoxD3* expression in Pax3GR/Zic1-GR injected explants treated with Meki (RDEA119) (**B**) or co-injected with Act-PI3K (**C**). Explants were cultured alongside sibling embryos and collected at late neurula stages (stage 18). Blocking MAPK activation or activating PI3K/Akt blocks expression of neural crest markers.](elife-33845-fig7){#fig7}

The above findings suggest that FGF signaling, and the differential utilization of Map Kinase and PI3 Kinase/Akt activation in pluripotent vs. lineage restricted cells, could play a role in the retention of stem cell attributes underlying the establishment of the Neural Crest state. We hypothesized that if this were the case, then either blocking Map Kinase signaling or prematurely activating PI3 Kinase/Akt might block formation of the Neural Crest. To test this, we again used Pax3/Zic1-mediated reprogramming to establish the Neural Crest state in explants, which leads to robust expression of the Neural Crest markers in these cells at stage 18 ([Figure 7b,c](#fig7){ref-type="fig"}). Notably, blocking Map Kinase signaling in these explants with RDEA119 interfered with establishing a Neural Crest state, as evidenced by reduced expression of both *FoxD3* (88%, n = 26) and *Sox9* (85%, n = 27) ([Figure 7b,c](#fig7){ref-type="fig"}). Similar results were found following forced activation of PI3 Kinase/Akt using Act-PI3K (*FoxD3*: 81%, n = 26; *Sox9*: 81%, n = 27). These findings provide strong evidence that retention of blastula-stage potential in the cells that will ultimately become the Neural Crest is controlled, at least in part, by retaining the high Map Kinase:low PI3 Kinase/Akt signaling profile essential to the pluripotency of blastula animal pole cells ([Figure 8](#fig8){ref-type="fig"}).

![Summary of the effects of MAPK or PI3K/Akt inhibition.\
(**A**) Schematic representation of MAPK and PI3K/Akt cascade activation in animal cap explants (staged by sibling embryos) at the blastula stage (stage 9), midgastrula stage (stage 11), and early neurula stage (stage 13). (**B**) Diagram summarizing the effects of MAPK or PI3K/Akt inhibition on the adoption of neural, epidermal, mesodermal, and endodermal states.](elife-33845-fig8){#fig8}

Discussion {#s3}
==========

Early embryonic cell fate decisions result from the interplay of a relatively small number of signaling pathways. Because these signals must be used reiteratively to direct a diverse array of outcomes, their output must be highly context-specific. Yet, in many cases, the mechanisms by which this is accomplished remain poorly understood. In this study, we uncover a striking switch in FGFR effector pathway utilization as cells transit from a pluripotent to a lineage-restricted state, adding important new insights into how FGF signaling regulates developmental potential. FGF-mediated Map Kinase activation is prominent in blastula stem cells prior to their exit from the pluripotent state, but then decreases as cells become lineage restricted. By contrast, FGF-mediated PI3 Kinase/Akt signaling is low in pluripotent cells, but increases dramatically as cells undergo lineage restriction. Importantly, both signaling cascades are blocked by dnFGFR4, showing that they are FGF mediated signals. However, although FGFR4 is the predominant FGF receptor expressed in blastula animal pole cells, it is not the only FGF receptor expressed there. It is possible that dnFGFR4 is also blocking the activity of other FGF receptors, such as FGFR1, as dominant negative proteins can sometimes inhibit the activity of related factors. We therefore interpret our findings using this receptor as demonstrating a role for FGF signaling in general, and not a specific role for FGFR4. Interesting, however, dnFGFR1 does not interfere with expression of neural crest markers in the manner that dnFGFR4 does ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

Given the striking switch in cascade activation as cells move from pluripotency to lineage restriction, we chose to focus on the roles played by these signaling cascades. We show that Map Kinase signaling is essential for the pluripotency of blastula stem cells, whereas PI3 Kinase/Akt signaling appears to play a role in the ability of these cells to adopt a subset of lineage restricted states. Crosstalk between the Map Kinase and PI3 Kinase/Akt pathways is known to be highly context dependent, and can be cooperative or antagonistic ([@bib1]). Indeed, antagonism between these pathways has been proposed to control the decision by angioblast progenitors to adopt artery versus venous fates ([@bib17]). It will therefore be of great interest to investigate the mechanisms via which the observed switch in pathway utilization is achieved in blastula stem cells. Our preliminary analysis of the gene expression changes that occur as cells progress from a pluripotent to a lineage restricted state suggests that this might be mediated, at least in part, by a change in expression of intracellular adaptor proteins that scaffold the Map kinase vs. PI3 Kinase cascades (Geary and LaBonne, unpublished). We cannot rule out, however, that there could be a switch in the utilization of different FGF receptors that may contribute to the change in pathway utilization. Further studies may shed light on the very different effects that FGF signaling has on the pluripotency of naïve vs. primed embryonic stem cell cultures ([@bib4]; [@bib26]; [@bib53]; [@bib15]; [@bib30]).

We interpret the findings reported here as evidence that in this system, FGF-mediated Map Kinase activity is required for the pluripotency of blastula stem cells. An alternative interpretation might be that these signals are required for exit from pluripotency. We favor the first interpretation for a number of reasons including the observation that pMap Kinase is high when these cells are pluripotent and down-regulated as they exit pluripotency, and that activating MEK prolongs the expression of the pluripotency marker *Sox3*. Moreover, blocking Map Kinase signaling does not prevent transit to a neuronal progenitor state, which it might if these signals controlled exit from pluripotency.

In *Xenopus*, FGF signaling had previously been implicated in the adoption of both mesodermal and neural states, and our current work lends new mechanistic insights into these studies. For example, FGF signaling has been shown to be required for activin-mediated mesoderm formation, but its contributions to this process remained unclear ([@bib29]). Our findings that FGF-mediated Map Kinase activation is required for the pluripotency of blastula animal pole cells provides a long sought explanation for this requirement. Our work also sheds light on the role of FGF signaling in neural induction mediated by BMP-antagonists ([@bib31]; [@bib47]). It has been shown that blocking FGF signaling with the tyrosine kinase inhibitor SU5402 does not prevent adoption of a definitive neural state in response to noggin, even though it can alter *Sox2/3* expression ([@bib56]). We find similar effects when blocking Map Kinase signaling, with Chordin-mediated *Sox2* expression blocked, but not *Nrp1* ([Figure 4](#fig4){ref-type="fig"}). Conversely, we find that blocking the PI3 Kinase/Akt cascade prevents transit to both a neural progenitor and definitive neural state., The latter finding confirms what has been described previously and attributed to PI3 Kinase/Akt regulating GSK3 and Wnt signaling ([@bib43]). Although we cannot rule out the possibility of cross-talk between these two signaling pathways, we report an earlier role for PI3 Kinase/Akt in mediating establishment of the neural progenitor state, prompting further exploration into a potential mechanism for its function during early ectodermal patterning. This could be linked to a recently described role for Akt in controlling progenitor cell progression ([@bib42]). The later role for PI3 Kinase/AKT signaling is consistent with the findings of Hongo and colleagues that a dominant negative FGFR4 inhibits commitment of animal cap cells to a neuronal state in response to neural-inducing cues ([@bib20]).

FGF signaling has also been previously implicated in the genesis of the neural crest ([@bib27]; [@bib37]; [@bib18]; [@bib39]; [@bib10]), although its role relative to BMP and Wnt signaling has remained unclear. Neural Crest stem cells are of central importance to the development and evolution of vertebrates ([@bib13]), and thus understanding the signals controlling their remarkable developmental potential is essential. Our recent work provides evidence that neural crest cells arise through partial retention of the regulatory network controlling the pluripotency of blastula ancestors ([@bib5]). Thus, it is crucial to re-examine the roles of signals, such as FGF, which had previously been hypothesized to 'induce' developmental potential in these cells, and ask if they might instead be acting earlier in development to control whether blastula animal pole cells become lineage restricted or retain pluripotency. Our findings that FGF-mediated Map Kinase signaling is required for the pluripotency of blastula animal pole cells supports such a model.

These findings led us to ask whether the striking change in FGF effector pathway utilization, from Map Kinase to PI3 Kinase/Akt, as cells transit from a pluripotent to a lineage restricted state could be important for the establishment of the Neural Crest population. Specifically, we wanted to know if the relative levels of Map Kinase and PI3 Kinase/Akt signals displayed by cells could predict or instruct the Neural Crest state. Strikingly, we found that cells that had been reprogrammed to a Neural Crest state by expression of Pax3 and Zic1 retained high levels of Map Kinase activity and low levels of Akt activity even at neurula stages, when control explants had become lineage restricted and transitioned to a high Akt, low Map Kinase activity state ([Figure 7a](#fig7){ref-type="fig"}). We found similar results when using an alternative regimen (Snail2 + Wnt signaling) for reprograming to a neural crest state (not shown) indicating that this signaling cascade signature correlates with the retention of pluripotency.

This correlation suggested that retaining a signature of high Map Kinase and low PI3 Kinase/Akt activity might be essential to establishing the Neural Crest stem cell population. We therefore asked if blocking Map Kinase activation and/or prematurely activating PI3 Kinase/Akt signals would interfere with reprograming animal pole explants to a Neural Crest state. Importantly, we found that the expression of *FoxD3* and *Sox9,* characteristic of the Neural Crest state established by Pax3/Zic1, was blocked by either inhibiting Map Kinase activity or prematurely activating Akt using a constitutively active PI3 Kinase subunit ([Figure 7b,c](#fig7){ref-type="fig"}). These data support a model in which context dependent control of effector pathways activated by FGF signaling in blastula animal pole cells controls not only the timing of the progression from pluripotency to lineage restriction of these cells, but also the retention of pluripotency and protection from lineage restriction in the cells that will become the Neural Crest. Our findings further suggest that the retention of FGF-mediated Map Kinase signaling in a subset of pluripotent blastula cells may have been an important step in the acquisition of Neural Crest cells, and thus in the evolution of vertebrates.

Materials and methods {#s4}
=====================

Embryological methods {#s4-1}
---------------------

Wildtype *Xenopus laevis* embryos were collected at the indicated stages and processed for in situ hybridization as previously described ([@bib27]). Manipulated whole embryos were microinjected into 1--2 cells at the 2--8 cell stage with mRNA (Ambion, mMessage mMachine SP6 Transcription Kit) as previously described ([@bib35]) and collected at blastula stages (stage 9) or midneurula stages (stage 15--17) for in situ hybridization. Inhibitor-treated whole embryos were treated with the chemical inhibitor Wortmannin (Sigma) at a final concentration of 750 nM and collected at early neurula stages (stage 15) for in situ hybridization. Animal cap explants were manually dissected from wildtype or manipulated stage 9 embryos and aged to the denoted stage in 1xMMR. Manipulated embryos used for these animal cap dissections include embryos injected into both cells at the two-cell stage with the denoted mRNA and embryos treated at the 2--4 cell stage with a specific chemical inhibitor. For Map Kinase inhibition (Meki), the highly specific Mek1/2 chemical inhibitor Refametinib (RDEA119, Selleckchem) was used. Fresh RDEA119 (50--100 μM) was added to the culture media of explants upon dissection from RDEA119 treated embryos. For PI3 Kinase inhibition (PI3Ki), the chemical inhibitors LY294 (Sigma) and Wortmannin (Sigma) were added to the culture media of explants dissected from stage 9 embryos. LY294 was used at a final concentration of 20 μM and Wortmannin was used at a final concentration of 100 nM. Both of these inhibitors can have off-target effects when used at higher doses. Pax3-GR and Zic1-GR explants were dissected from injected embryos treated with 15 μM Dexamethasone (Sigma) at stage 9 as previously described ([@bib5]). All results are representative of a minimum of three independent experiments.

RNA isolation, CDNA synthesis, and qRT-PCR {#s4-2}
------------------------------------------

RNA isolation, cDNA synthesis, and qPCR was performed as previously described ([@bib5]). Primers used include FoxD3, MyoD, ornithine decarboxylase (ODC), Sox2, Sox3, Sox11, Snail1, Sox17, Zic1, and Zic2 (sequences below). Expression was normalized to ODC and fold change calculated using ΔΔCT relative to stage 9 or stage 13 control samples. Represented is the mean of three independent biological replicates, with error bars depicting the standard error of the mean (SEM). An unpaired, two-tailed t-test was used to determine significance.

GeneForwardReverseFoxD3TCC TCT GAA CTG ACC AGG AATGC CGA CAC CCC AAT AAT GTMyoDCTG CTC CGA CGG CAT GAATCC CAA GTC TCA CGT CAT TGODCTGA AAA CAT GGG TGC CTA CATGC CAG TGT GGT CTT GAC ATSox2TCA CCT CTT CTT CCC ATT CGCGA CAT GTG CAG TCT GCT TTSox3CAC AAC TCG GAG ATC AGC AATCG TCG ATG AAG GGT CTT TTSox11GAA CTT CAC CCA GCA GAA CCCCC TCG CTA CAA GAG TCC AASox17GCA AGA TGC TTG GCA AGT CGGCT GAA GTT CTC TAG ACA CASnail1AAG TCT CCC ATC AGC CCT TCAGT CTT GCC CCC TTC ATC TTZic1CCT GGA TGT GGC AAA GTC TTGTC ACA GCC TTC AAA CTC GCZic2AAT CCA CAA GAG GAC TCA CAGTG TGC ACG TGC ATG TGC TT

Activin treatment of animal cap explants {#s4-3}
----------------------------------------

Animal cap explants were isolated from control or manipulated blastula (stage 9) embryos. Following dissection, explants were cultured with recombinant Activin protein (R and D Systems) at a final concentration of 20--40 ng/mL for mesoderm induction and 100 ng/mL for endoderm induction in 1xMMR supplemented with 0.1% BSA as a carrier. Explants were cultured to midgastrula and midneurula stages (stage 11.5--16) following mesoderm induction and midgastrula stages (stage 11.5) following endoderm induction and processed for in situ hybridization.

Western blot analysis {#s4-4}
---------------------

For western blot analyses, animal cap explants (10--20 explants) or whole embryos (five embryos) were lysed using a fresh 50 mM HEPES lysis buffer containing 5 mM EDTA, 2 mM Sodium Orthovanadate, 20 mM Sodium Fluoride, 10 mM β-Glycerophosphate, 1 mM Sodium Molybdate dihydrate, PhosStop phosphatase inhibitors (Roche), and protease inhibitors described previously ([@bib35]). Animal cap explants were dissected from either wildtype or manipulated blastula (stage 9) embryos and cultured in 1XMMR until the indicated stage and collected. Stage 9 explants were collected 1 hr post-dissection. For the RDEA119 and LY294 time series, wildtype explants were dissected, cultured for 1 hr in 1X MMR for stage 9 treatment or cultured to stage 13, and subsequently cultured in inhibitor-containing media for the denoted length of time prior to collection. For Pax3-GR and Zic1-GR explant analysis, both control and Pax3-GR and Zic1-GR explants were cultured for 1 hr in 1XMMR, treated with 15 μM Dexamethasone, and then collected at the indicated stage. SDS-PAGE and Western blot analysis was used to visualize proteins, which were detected using the following antibodies: p44/42 MAPK (Erk1/2) (1:2000, Cell Signaling Technology), Phospho-p44/42 (Erk1/2) (Thr202/Tyr204) XP (1:2000, Cell Signaling Technology), Akt (1:2000, Cell Signaling Technology), Phospho-Akt (Ser473) XP (1:2000, Cell Signaling Technology), and Actin (1:8000, Sigma-Aldrich,St. Louis, MO). Corresponding secondary antibodies conjugated to horseradish peroxidase (HRP) and chemiluminescense was used.

DNA constructs {#s4-5}
--------------

The truncated *Xenopus laevis* FGFR4 (AB007036) construct used (dnFGFR4) was cloned into a pCS2 vector from dnFGFR4-cs108, a kind gift from R. Harland (University of California, Berkeley). The dominant-negative PI3 Kinase subunit (dnPI3K, or Δp85) and constitutively-active PI3 Kinase subunit (Act-PI3K, or p110caax) was a gift from Chenbei Chang (University of Alabama), and constitutively-activate Mek (Act-Mek) was a gift from Ira Daar (National Cancer Institute, Maryland). Dominant-negative Raf (dnRaf) was generated by quick change mutagenesis (hRaf S621A) and subcloned into pCS2. All constructs received and cloned were confirmed by sequencing.
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Editors' note: a previous version of this study was rejected after peer review, but the authors submitted for reconsideration. The first decision letter after peer review is shown below.\]

Thank you for choosing to send your work, \"FGF mediated MAPK and PI3K/Akt Signals make distinct contributions to pluripotency and the establishment of Neural Crest\", for consideration at *eLife*.

Your submission has been assessed by a Senior and Reviewing Editor, Marianne Bronner, and three reviewers who have elected to remain anonymous. The reviewers found the paper to be potentially interesting and well-written. However, they also felt the authors need to strengthen biochemical characterization of the pathway and confirm that this proposed \"molecular switch\" is downstream of the receptor. To accomplish this the authors would have to collect persuasive evidence linking Akt to FGF by demonstrating dnFGFR4 specificity, using other means of interfering with pathways downstream of FGF, and using more markers to prove their point. In addition, they should better discuss previous literature on this topic as well as alternative interpretations of their data. In general, it was felt that the present manuscript is a description of a phenomenon rather than a molecular characterization of a new mechanism. Please see the individual reviews below for further details.

Given that these revisions are likely to take a significant amount of time and the policy of *eLife* is to reject papers that require more than two months for modifications, we have no choice but to decline the present version of the paper. That said, if you feel you can make the revisions, we will make every effort to return a new version of the manuscript to the same reviewers.

*Reviewer \#1:*

Geary and LaBonne describe differential activation of the downstream effector pathways of FGF-signaling in pluripotent and lineage-restricted *Xenopus* cells. They utilize animal cap assays to show that blastula stem cells have high levels of MAP Kinase signaling, while cells that are differentiating have prevalence of PI3 Kinase/Akt signals -- both downstream of FGFs. The authors suggest that the transition between these two effector pathways, which takes place during gastrulation, is required for the establishment of distinct cell lineages. Furthermore, reprogramming experiments are employed to show that maintenance of high MAP Kinase signaling is required for the establishment of the neural crest population. In line with their previous work, the authors suggest that maintenance of FGF/MAPK signaling from blastula stages is necessary for specification of the neural crest and might underlie its multipotency.

The manuscript is well written and the results are presented clearly. The switch in FGF effector deployment is an exciting phenomenon that holds important implications for the mode of action of signaling pathways during early development. Whereas the authors convincingly tie this molecular switch to cellular properties such as multipotency, the fact that virtually all experiments are performed in animal cap assays raises substantial concerns about the validity of the authors\' findings in vivo. Thus, evidence of the presence of the MAPK-PI3K switch in developing embryos would be an important addition to the work.

Major points:

1\) Lack of in vivo experiments: The authors employ animal cap assays for both loss and gain of function experiments, and to test questions pertaining to cell potential of blastula and neural crest cells. Validation of the FGF effector switch in vivo would greatly enhance the work. In particular, I was puzzled by the reprogramming experiments -- why not examine neural crest formation as it takes place in a developing embryo instead of artificially generating neural crest-like cells through overexpression?

2\) On the central role ascribed to FGFR4: Throughout the text, the authors state that activation of the MAP Kinase and the PI3 Kinase/Akt pathways are downstream of FGFR4. This claim is based on the expression levels of FGF receptors in the early *Xenopus* embryo (data not shown), and the use of a FGFR4 dominant negative construct, which causes loss of both Erk and Akt phosphorylation. Given the promiscuity of dnFGFR constructs and the presence of multiple FGF receptors in the blastula/neural crest, I am not convinced that FGFR4 is the main trigger of the MAPK and PI3 effector pathways. Instead, I am tempted to speculate that the switch occurs due to activation of a different FGFR type or isoform. The central role of FGFR4 in this process can only be confirmed by specific knockdown of this transcript.

3\) Crosstalk between FGF effector pathways: Since intracellular effector pathways of signaling systems are very complex and known to intersect, how does activation/inhibition of PI3K affect activity of MAPK and vice versa? Are the effector pathways inhibiting each other as one might speculate from [Figure 3](#fig3){ref-type="fig"} and Table 1?

4\) Possible mechanisms of the molecular switch: While characterization of the molecular mechanism controlling the switch between effector pathways may be beyond the scope of the work, as I reader I expected to find this point addressed in the Discussion. What would be the factors that could tilt the balance between MAPK and PI3K, specifically during gastrula stages?

*Reviewer \#2:*

This manuscript makes advances in the understanding of pluripotency of the \"animal cap\" which here is referred to as pluripotent ectoderm, in line with the hypothesis that Neural crest is the retention of a pluripotent state. This case was made in a previous paper, and the current work builds on that.

This manuscript makes the case that FGF acting through FGFR4, and MAPkinase maintains pluripotency. In contrast, Akt/PI3Kinase terminate pluripotency.

The manuscript builds a circumstantial case for the importance of FGFR4 in maintaining pluripotency, but the results are based on a dominant negative receptor, whose specificity has not been proven. Therefore discussion regarding FGFR4 dominant negatives, and whether this manipulation implicated FGFR4 specifically in signaling needs to be tightened up or experimentally verified.

The results with FGFR4 appear to be very different from those from Hongo/Okamoto, who essentially argued the opposite, that DN FGFR4 blocks anterior neural induction. The precise experiments seem different, but it would be very useful to arrive at a coherent explanation if possible.

The most interesting aspect of the work is the distinction between Akt/PI3K activity in not being required for pluripotency, and Mapkinase activity requirement for pluripotency. One would expect that this would be more thoroughly documented, using independent inhibitors of the pathways, and assaying additional consequences of pluripotency, in addition to Epidermal Keratin. I don\'t think this would be an unusual request, but is in line with the general view that pharmacological manipulations, where possible should be backed up with additional drug or molecular manipulation.

With respect to the inhibition of progression of the cells to neural states with the PI3K inhibitor, it would be essential to know what the cells are doing instead (presumably retaining pluripotency markers?). It is important to rule out the possibility that this does not simply cause cell death, or general ill health of the cells, which would also prevent maturation of the cells, which some have argued accounts for the failure of neutralization when FGF is inhibited (Wills, Harland).

With respect to the requirement for both MapKinase and PI3Kinase pathways being required for mesoderm induction, the manuscript should refer to previous work on this, such as Umbhauer and Smith, and Carballada, Lemaire. Their results appear to be similar, so perhaps this is not new.

[Figure 6A](#fig6){ref-type="fig"} is not very compelling -- the premature downregulation of Sox3 by p110-Caax and the retention of Sox3 by MAPK should be quantified more convincingly.

[Figure 7C and D](#fig7){ref-type="fig"} are not very compelling; again some quantification would be useful.

*Reviewer \#3:*

In this manuscript, the authors investigate the signalling requirements for *Xenopus* animal caps to remain in a multipotent state or to differentiate into different ectodermal derivatives (epidermis/neural) or other germ layers (endoderm/mesoderm). FGF signalling is well known to be important for the regulation of pluripotency in mouse and other species, hence they focus on FGF.

The authors show that FGF signalling via FGFR4 is required for early blastula animal caps to become epidermis, and that as animal caps age they switch from high MAPK to high Akt signalling, while losing MAPK activity. While the acquisition of epidermal fate depends on MAPK signalling, the acquisition of neural identity after Chordin injection requires Akt, thus, both pathways are required differentially. They then go on to show that the same is true for the acquisition of endodermal (MAPK dependent) and mesoderm (Akt dependent) fates.

Next, they aim to assess whether prolonged MAPK or premature Akt activation alters animal cap \'pluripotency\' (only assessed by Sox3) and suggest that this indeed changes the retention of pluripotent character.

Finally, the authors have previously shown that neural crest cells have retained pluripotency rather than undergoing lineage restriction. They now assess whether induction of neural crest cells by a combination of transcription factors alters MAPK or Akt signalling and show that this indeed activates MAPK, but not Akt, and that MAPK inhibition or Akt overactivation prevents neural crest induction by these factors.

They conclude that MAPK is essential for the pluripotency state, while Akt is important for animal caps to adopt some lineages.

I am somewhat concerned about the novelty of their findings and about the final interpretation of the results with a central conclusion relying on a single marker. Modulation of FGF signalling during pluripotency and the loss thereof is well established, and in this sense the study adds detail to a well-established principle rather than revealing novel concepts. Of course it is interesting how different downstream pathways act differentially, however this in itself is not a new principle.

A central part of their conclusion is that MAPK mediated FGF signalling is required for cells to maintain pluripotency (e.g. Discussion, second paragraph). However, they never show that pluripotency makers depend on MAPK -- they only ever examine Oct60 and Sox3 with Sox3 also being expressed in neural tissue. This is not sufficient to make a general conclusion about pluripotency. In [Figure 6](#fig6){ref-type="fig"} they show that prolonged MAPK activation leads to prolonged Sox3 expression, while activation of Akt does the opposite. They equate this to retaining pluripotency. However, as they themselves show in [Figure 2](#fig2){ref-type="fig"}, they consider Sox3 as neural marker and argue that this is indeed neural tissue because it does not express Oct60. They must demonstrate that in the experiment in [Figure 6](#fig6){ref-type="fig"} Oct60 and other \'pluripotency makers\' are affected and that MAPK inhibition leads to loss of pluripotency genes. For this to be convincing they have to demonstrate a panel of genes rather than just one.

The authors argue that retaining MAPK activity is key for retaining pluripotency in neural crest cells. However they do not show this; they show that neural crest induction by Pax3/Zic1 elevates FGFR4 expression and MAPK suggesting that these changes in signalling activity is a consequence of neural crest cell formation, but not the driver.

In [Figure 2](#fig2){ref-type="fig"} the authors show that dnFGFR4 enhances neural markers (sox3, nrp1). They then go on to show that Akt signalling is required for cells to become neutralised when injected with chordin ([Figure 4](#fig4){ref-type="fig"}). These results are contradictory, and the first result is inconsistent with findings that FGF is required for neural induction. Does Akt or MAPK inhibition enhance neural gene expression similar to what is shown in [Figure 2B](#fig2){ref-type="fig"}?

In summary, while the experiments are generally well conducted and controlled the results appear to be overinterpreted often depending on a single marker and the conclusions are rather forceful. The involvement of FGF in pluripotency is well established, although a potential differential role if this can be proven may be interesting.

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for submitting your article \"FGF mediated MAPK and PI3K/Akt Signals make distinct contributions to pluripotency and the establishment of Neural Crest\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Marianne Bronner as the Senior and Reviewing Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The reviewers find the manuscript improved. However, they think that some of the conclusions overreach the data and that parts of the manuscript should be rewritten and softened, as described below:

Essential revisions:

1\) Since the additional experiments examining the role of FGFR4 were not definitive, we ask that you rewrite this part of the manuscript to make it clear that a possible role for FGFR4 is speculative. While it may have a role in the process, the evidence is not definitive and the mechanism by which the DNFGFR1 construct has effects different from DNFGFR1 is unresolved.

2\) It\'s unclear if the experiment with the DNFGFR1 is of any significance and feels like an afterthought. This would also impact the Discussion since it is possible that the switch between MAPK and PI3K involves activation of distinct receptors.

10.7554/eLife.33845.020

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

> Reviewer \#1:
>
> \[...\] 1) Lack of in vivo experiments: The authors employ animal cap assays for both loss and gain of function experiments, and to test questions pertaining to cell potential of blastula and neural crest cells. Validation of the FGF effector switch in vivo would greatly enhance the work. In particular, I was puzzled by the reprogramming experiments -- why not examine neural crest formation as it takes place in a developing embryo instead of artificially generating neural crest-like cells through overexpression?

These experiments were done in explants because in those you can monitor the progression from pluripotency to lineage restricted without influence from other tissues and signals, allowing the experiments to be more tightly controlled. This also allows separation from the confounded role of FGF signaling in posteriorization of the embryonic axes. In this work we were focused on how pluripotent blastula (ES) cells retain their pluripotency, and this was best explored by isolating them. Also, because pharmacological inhibitors lack spatial control, you cannot be certain that the phenotypic effects are direct on the tissue of interest when working with intact embryos. Nonetheless, in the revised manuscript we have now included whole embryo experiments as supplements to [Figures 1](#fig1){ref-type="fig"} and [7](#fig7){ref-type="fig"} confirming the effects of these pathways on neural crest endogenously.

> 2\) On the central role ascribed to FGFR4: Throughout the text, the authors state that activation of the MAP Kinase and the PI3 Kinase/Akt pathways are downstream of FGFR4. This claim is based on the expression levels of FGF receptors in the early Xenopus embryo (data not shown), and the use of a FGFR4 dominant negative construct, which causes loss of both Erk and Akt phosphorylation. Given the promiscuity of dnFGFR constructs and the presence of multiple FGF receptors in the blastula/neural crest, I am not convinced that FGFR4 is the main trigger of the MAPK and PI3 effector pathways. Instead, I am tempted to speculate that the switch occurs due to activation of a different FGFR type or isoform. The central role of FGFR4 in this process can only be confirmed by specific knockdown of this transcript.

We agree that we have not ruled out the possibility that the dnFGFR4 does not block the activity of other FGFRs and we now discuss this in the text, and make clear that we are blocking FGF signaling, but not necessarily only FGFR4 signaling. We also include data showing that dnFGFR1 does not have the same effects on neural crest that dnFGFR4 does. We note that in response to the reviews we did attempt to morpholino deplete FGFR4 vs FGFR1 -- we purchased four published MOs for these receptors listed on the Xenbase site, but we found they tended to crash out of solution and were not useful for loss of function assays. We asked Gene Tools to look at the sequences, and opined that they were poorly designed and predicted to be insoluble. Rather than spend more money on morpholinos, we have more recently been trying to use G0-CRiSPR mutagenesis to deplete these receptors. Unfortunately we have not been able to get early and uniform enough mutagenesis to do these experiments (plus the receptors are maternally provided) and we have delayed publication of this work as long as we can. We had never meant to emphasize the role of one particular receptor in this work (we used FGFR4 because this receptor is the predominant one expressed at blastula stages) -- our focus has always been on the downstream effector pathways of FGF signaling and their functions and we make that clear in the text.

> 3\) Crosstalk between FGF effector pathways: Since intracellular effector pathways of signaling systems are very complex and known to intersect, how does activation/inhibition of PI3K affect activity of MAPK and vice versa? Are the effector pathways inhibiting each other as one might speculate from [Figure 3](#fig3){ref-type="fig"} and Table 1?

[Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} now shows the specificity of the Mek and PI3K inhibitors for their own pathways.

> 4\) Possible mechanisms of the molecular switch: While characterization of the molecular mechanism controlling the switch between effector pathways may be beyond the scope of the work, as I reader I expected to find this point addressed in the Discussion. What would be the factors that could tilt the balance between MAPK and PI3K, specifically during gastrula stages?

We now address this point in the Discussion. We believe that the context/competency of the cells changes over time, and that changes in the expression of intracellular FGF pathway adaptors/modulators over developmental time likely underlies the switch in effector pathway utilization. We agree that experiments on this are beyond the scope of the current work.

> Reviewer \#2:
>
> \[...\] The manuscript builds a circumstantial case for the importance of FGFR4 in maintaining pluripotency, but the results are based on a dominant negative receptor, whose specificity has not been proven. Therefore discussion regarding FGFR4 dominant negatives, and whether this manipulation implicated FGFR4 specifically in signaling needs to be tightened up or experimentally verified.
>
> The results with FGFR4 appear to be very different from those from Hongo/Okamoto, who essentially argued the opposite, that DN FGFR4 blocks anterior neural induction. The precise experiments seem different, but it would be very useful to arrive at a coherent explanation if possible.

The reviewer refers to a 1999 DB paper that focused on a role for FGF signaling in anterior neural induction that used dnFGFR1 and dnFGFR 4 constructs. The reviewer is correct that the experiments in that paper are done quite differently than ours: explants were isolated at gastrula stages (stage 10), a number of the experiments were done with dissociated cells, and changes in gene expression were largely analyzed by RT-PCR assays at stage 25 with only two genes in common to our study. With so many differences it's how to come up with a single explanation for why the results differ. We can only report the results of our experiments, which focused on earlier stages and which were all carried out numerous times with highly reproducible results.

> The most interesting aspect of the work is the distinction between Akt/PI3K activity in not being required for pluripotency, and Mapkinase activity requirement for pluripotency. One would expect that this would be more thoroughly documented, using independent inhibitors of the pathways, and assaying additional consequences of pluripotency, in addition to Epidermal Keratin. I don\'t think this would be an unusual request, but is in line with the general view that pharmacological manipulations, where possible should be backed up with additional drug or molecular manipulation.

In the revised manuscript we have repeated all of the experiments with at least one additional way of inhibiting each pathway. We now use dnRaf, in addition to the Mek inhibitors, for Mapk inhibition. We use Wortmanin and Ly294, in addition to dnPI3K, for Akt inhibition. We also use multiple markers for each cell fate examined (EpK and Trim29 for epidermis; Xbra and MyoD for mesoderm; Sox17 and endodermin for endoderm; *Sox2*/3 and Nrp1 for neural etc.). We examine pluripotency both by marker expression and by functional tests of pluripotency. We also now include qPCR data quantifying gene expression changes in response to inhibition of each pathway.

> With respect to the inhibition of progression of the cells to neural states with the PI3K inhibitor, it would be essential to know what the cells are doing instead (presumably retaining pluripotency markers?). It is important to rule out the possibility that this does not simply cause cell death, or general ill health of the cells, which would also prevent maturation of the cells, which some have argued accounts for the failure of neutralization when FGF is inhibited (Wills, Harland).

The revised manuscript includes qPCR data examining the changes in gene expression in explants inhibited for each pathway. In the case of the PI3K inhibitor there is an interesting up-regulation of a broad set of lineage markers, suggesting that the cells are poised for lineage decisions but impaired in their decision making. We were also very careful to use low doses of inhibitors such as LY294 as they can have off target effects at higher doses. For our studies we titrated our doses to the lowest level sufficient to completely block Akt activation, which is 3-10 fold lower than doses used in some studies and which can generate nonspecific effects, so we are confident that these changes in gene expression are specific to this pathway.

> With respect to the requirement for both MapKinase and PI3Kinase pathways being required for mesoderm induction, the manuscript should refer to previous work on this, such as Umbhauer and Smith, and Carballada, Lemaire. Their results appear to be similar, so perhaps this is not new.

These papers are now cited/discussed. These pathways have indeed been implicated in mesoderm induction previously. What differs here is how that finding is interpreted. Those studies, and those of LaBonne and Whitman, focused on a single lineage decision. Our current work is focused on pluripotency and lineage decisions more broadly. We thus provide a new interpretation of those prior findings and put them in a broader context. For example, with respect to Mapk, we propose a general effect on pluripotency rather than a specific effect on mesoderm.

> [Figure 6A](#fig6){ref-type="fig"} is not very compelling -- the premature downregulation of Sox3 by p110-Caax and the retention of Sox3 by MAPK should be quantified more convincingly.

We have both replaced the images and included qPCR data here.

> [Figure 7C and D](#fig7){ref-type="fig"} are not very compelling; again some quantification would be useful.

We have provided better images for these data. Other typos and references errors noted in the review have been corrected and we thank the reviewer for prompting these changes, which have improved the manuscript.

> Reviewer \#3:
>
> \[...\] I am somewhat concerned about the novelty of their findings and about the final interpretation of the results with a central conclusion relying on a single marker. Modulation of FGF signalling during pluripotency and the loss thereof is well established, and in this sense the study adds detail to a well-established principle rather than revealing novel concepts. Of course it is interesting how different downstream pathways act differentially, however this in itself is not a new principle.

We respectfully disagree about the novelty of these findings. First, a role for FGF in pluripotencyhad not been shown in this system, which is the system in which a lot of prior work on germ layer formation had been carried out. Indeed FGF had been ascribed very different roles in the *Xenopus* system, which did not integrate very well with findings in mouse and human ES cells. We feel therefore that our results advance the field by showing the central role this signaling is playing in pluripotency is evolutionarily conserved. Our work also further advances the field by adding exciting and very novel data on a switch in effector pathways. This finding is not only important in its own right, but also may help explain differences in what FGF signaling does in naive vs. primed ES (and human vs. mouse) cells. Finally, we show a completely novel role for FGF dependent Map kinase signaling in the retention of pluripotency that led to neural crest formation, providing a significant mechanistic advance over our prior Science paper.

> A central part of their conclusion is that MAPK mediated FGF signalling is required for cells to maintain pluripotency (e.g. Discussion, second paragraph). However, they never show that pluripotency makers depend on MAPK -- they only ever examine Oct60 and Sox3 with Sox3 also being expressed in neural tissue. This is not sufficient to make a general conclusion about pluripotency. In [Figure 6](#fig6){ref-type="fig"} they show that prolonged MAPK activation leads to prolonged Sox3 expression, while activation of Akt does the opposite. They equate this to retaining pluripotency. However, as they themselves show in [Figure 2](#fig2){ref-type="fig"}, they consider Sox3 as neural marker and argue that this is indeed neural tissue because it does not express Oct60. They must demonstrate that in the experiment in [Figure 6](#fig6){ref-type="fig"} Oct60 and other \'pluripotency makers\' are affected and that MAPK inhibition leads to loss of pluripotency genes. For this to be convincing they have to demonstrate a panel of genes rather than just one.

The strongest and most relevant data in assessing pluripotency comes from functional studies that challenge cells to adopt different fates/states. Those pluripotency experiments are shown in [Figures 3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}, and each fate/state is evaluated with more than one marker. We believe these data collective provide compelling evidence for a loss of pluripotency. In addition we examine changes in the expression of a panel of genes in response to inhibitor treatment in [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}.

> The authors argue that retaining MAPK activity is key for retaining pluripotency in neural crest cells. However they do not show this; they show that neural crest induction by Pax3/Zic1 elevates FGFR4 expression and MAPK suggesting that these changes in signalling activity is a consequence of neural crest cell formation, but not the driver.

We do show that establishing a neural crest state using Pax3/zip retains pMapK (and FGFR4 expression), however we also more directly show in [Figure 7](#fig7){ref-type="fig"} that blocking Map kinase activation blocks expression of neural crest markers *Sox9* and *Foxd3* in explants. In addition, in [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}, we show that dnRaf blocks neural crest formation in whole embryos.

> In [Figure 2](#fig2){ref-type="fig"} the authors show that dnFGFR4 enhances neural markers (sox3, nrp1). They then go on to show that Akt signalling is required for cells to become neutralised when injected with chordin ([Figure 4](#fig4){ref-type="fig"}). These results are contradictory, and the first result is inconsistent with findings that FGF is required for neural induction. Does Akt or MAPK inhibition enhance neural gene expression similar to what is shown in [Figure 2B](#fig2){ref-type="fig"}?

The level of Sox3/Nrp1 expression found in dnFGFR4 explants is much weaker than observed in chordin-neuralized explants (now shown in [Figure 2](#fig2){ref-type="fig"}). We think this represents a bias toward a neuronal progenitor state but not neural induction. Blocking Mapk activation does not affect chordin-mediated neural induction, but blocking Akt activation does, as the reviewer notes. Interestingly blocking Akt also leads to weak upregulation of *Sox2* and Sox3 along with other lineage markers (see Figure 4---figure supplement 2), which we interpret as evidence that the cells are poised for lineage decisions, but impaired in their decision making. We don't find these data contradictory but rather that it reflects the complexity of signaling systems, and blocking any one downstream signaling cascade may not fully recapitulate blocking all downstream signals. It should be noted that FGF signaling is not required for neural induction/anterior neural development in *Xenopus* (BMP antagonism is sufficient for this, see Wills et al. 2010 for example) but has been shown to be essential for posterior neural development.

\[Editors\' note: the author responses to the re-review follow.\]

> Essential revisions:
>
> 1\) Since the additional experiments examining the role of FGFR4 were not definitive, we ask that you rewrite this part of the manuscript to make it clear that a possible role for FGFR4 is speculative. While it may have a role in the process, the evidence is not definitive and the mechanism by which the DNFGFR1 construct has effects different from DNFGFR1 is unresolved.

We have rewritten these parts of the manuscript to reflect this.

> 2\) It\'s unclear if the experiment with the DNFGFR1 is of any significance and feels like an afterthought. This would also impact the Discussion since it is possible that the switch between MAPK and PI3K involves activation of distinct receptors.

We have added this to the Discussion.
